



PEER-REVIEW REPORT

Name of journal: *World Journal of Experimental Medicine*

Manuscript NO: 99239

Title: Melanocortin 4 receptor (M₄R) mutation in obesity

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05751232

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: India

Manuscript submission date: 2024-07-18

Reviewer chosen by: Jia-Lin Zhang

Reviewer accepted review: 2024-08-02 00:25

Reviewer performed review: 2024-08-14 10:39

Review time: 12 Days and 10 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



Scientific significance of the conclusion in this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

These were largely due to the complex intracellular signalling by Melanocortin 4 receptor, and the understanding by the Melanocortin 4 receptor receptor, its expression and downstream signalling enabled the identification of agonists which mimic its physiological actions. This article is very innovative and provides good ideas for the potential pathogenesis and intervention measures of obesity, which is worth learning for researchers. The article has a clear train of thought, abundant research literature included, and can closely analyze and discuss the relationship between MC4R and obesity--The hypothalamic leptin-melanocortin pathway is central to the regulation of appetite and weight, where leptin activates proopiomelanocortin (POMC) neurons, leading to the production of melanocortin peptides; these in turn act on melanocortin 4 Receptor to suppress appetite and increase energy expenditure. Melanocortin 4 receptor mutations are responsible for syndromic and non-syndromic obesity. as well as potential mechanisms of action. It has good logic and clear hierarchy , Setmelanotide, a Melanocortin 4 receptor agonist has been approved for use in the treatment of obesity due to Melanocortin 4 receptor mutations. It did not have adverse effects on heart and



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568

E-mail: office@baishideng.com

https://www.wjgnet.com

blood pressure in humans while having a substantial weight loss effect, with a favourable therapeutic index. Setmelanotide, a Melanocortin 4 receptor agonist has been approved for use in the treatment of obesity due to Melanocortin 4 receptor mutations. It did not have adverse effects on heart and blood pressure in humans while having a substantial weight loss effect, with a favourable therapeutic index. The same time, In addition to MC4R agonists and antagonists, inverse agonists are potential areas for investigation; these include AgRP and its mimics for Melanocortin 4 receptor.